CPI 1205

Drug Profile

CPI 1205

Alternative Names: CPI1205

Latest Information Update: 28 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Constellation Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action EZH2 enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cancer; Prostate cancer
  • Preclinical Multiple myeloma
  • No development reported B cell lymphoma

Most Recent Events

  • 28 Apr 2018 No recent reports of development identified for phase-I development in B-cell lymphoma(Second-line therapy or greater) in USA
  • 05 Mar 2018 Efficacy, pharmacokinetics and adverse events data from a phase I trial in Cancer presented at the 16th International Congress on Targeted Anticancer Therapies (TAT-2018)
  • 16 Jan 2018 Phase I/II clinical trials in Cancer (Combination therapy) (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top